Citations (49)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Somnath Ghosal & Subrata Banerjee. (2022) Investigating the potential molecular players and therapeutic drug molecules in carfilzomib resistant multiple myeloma by comprehensive bioinformatics analysis. Leukemia & Lymphoma 63:11, pages 2545-2556.
Read now
Read now
A. M. U. B. Mahfuz, Felipe Stambuk Opazo, Luis F. Aguilar & Muhammad Nasir Iqbal. (2022) Carfilzomib as a potential inhibitor of NADH-dependent enoyl-acyl carrier protein reductases of Klebsiella pneumoniae and Mycobacterium tuberculosis as a drug target enzyme: insights from molecular docking and molecular dynamics. Journal of Biomolecular Structure and Dynamics 40:9, pages 4021-4037.
Read now
Read now
Xavier Leleu, Ajai Chari, Shambavi Richard, Monica Khurana, Akeem Yusuf & Saad Z. Usmani. (2021) A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly. Expert Review of Hematology 14:12, pages 1049-1058.
Read now
Read now
Patrick Roth, Warren P. Mason, Paul G. Richardson & Michael Weller. (2020) Proteasome inhibition for the treatment of glioblastoma. Expert Opinion on Investigational Drugs 29:10, pages 1133-1141.
Read now
Read now
Articles from other publishers (45)
Rachel Kandel, Jasmine Jung & Sonya Neal. (2024) Proteotoxic stress and the ubiquitin proteasome system. Seminars in Cell & Developmental Biology 156, pages 107-120.
Crossref
Crossref
Shifeng Long, Shengping Long, Honglei He, Liang Luo, Mei Liu & Ting Ding. (2023) Exosomal miR-182 derived from bone marrow mesenchymal stem cells drives carfilzomib resistance of multiple myeloma cells by targeting SOX6. Journal of Orthopaedic Surgery and Research 18:1.
Crossref
Crossref
Christine N. Habib, Alaa E. Ali, Nahla H. Anber & Mina Y. George. (2023) Lactoferrin ameliorates carfilzomib-induced renal and pulmonary deficits: Insights to the inflammasome NLRP3/NF-κB and PI3K/Akt/GSK-3β/MAPK axes. Life Sciences 335, pages 122245.
Crossref
Crossref
Angelica Ferro, Evangelia Pantazaka, Constantinos M. Athanassopoulos & Muriel Cuendet. (2023) Histone deacetylase‐based dual targeted inhibition in multiple myeloma. Medicinal Research Reviews 43:6, pages 2177-2236.
Crossref
Crossref
Boranai Tychhon, Jesse C. Allen, Mayra A. Gonzalez, Idaly M. Olivas, Jonathan P. Solecki, Mehrshad Keivan, Vanessa V. Velazquez, Emily B. McCall, Desiree N. Tapia, Andres J. Rubio, Connor Jordan, David Elliott & Anna M. Eiring. (2023) The prognostic value of 19S ATPase proteasome subunits in acute myeloid leukemia and other forms of cancer. Frontiers in Medicine 10.
Crossref
Crossref
Luai Madanat, Ruby Gupta, Paul Weber, Navneet Kumar, Rohit Chandra, Hycienth Ahaneku, Yatharth Bansal, Joseph Anderson, Abhay Bilolikar & Ishmael Jaiyesimi. (2023) Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth
Review. Current Cardiology Reviews 19:3.
Crossref
Crossref
Karan L. Chohan & Prashant Kapoor. (2023) BTK Inhibitors and Other Targeted Therapies in Waldenström Macroglobulinemia. Hemato 4:2, pages 135-157.
Crossref
Crossref
Weam Othman Elbezanti, Kishore B. Challagundla, Subash C. Jonnalagadda, Tulin Budak-Alpdogan & Manoj K. Pandey. (2023) Past, Present, and a Glance into the Future of Multiple Myeloma Treatment. Pharmaceuticals 16:3, pages 415.
Crossref
Crossref
Mahmood Barani, Mohammad Reza Hajinezhad, Sheida Shahraki, Shekoufeh Mirinejad, Mahtab Razlansari, Saman Sargazi, Abbas Rahdar & Ana M. Díez-Pascual. (2023) Preparation, characterization, and toxicity assessment of carfilzomib-loaded nickel-based metal-organic framework: Evidence from in-vivo and in-vitro experiments. Journal of Drug Delivery Science and Technology 81, pages 104268.
Crossref
Crossref
Ricardo Lemes Gonçalves, Gabriel Augusto Pires de Souza, Mateus de Souza Terceti, Renato Fróes Goulart de Castro, Breno de Mello Silva, Romulo Dias Novaes, Luiz Cosme Cotta Malaquias & Luiz Felipe Leomil Coelho. (2022) Integrative transcriptome analysis of SARS-CoV-2 human-infected cells combined with deep learning algorithms identifies two potential cellular targets for the treatment of coronavirus disease. Brazilian Journal of Microbiology 54:1, pages 53-68.
Crossref
Crossref
Yuval Harris, Hagit Sason, Danna Niezni & Yosi Shamay. (2022) Automated discovery of nanomaterials via drug aggregation induced emission. Biomaterials 289, pages 121800.
Crossref
Crossref
Cheherazade Trouki, Giovanni Barcaro & Susanna Monti. (2022) Exploring the mechanisms of drug-delivery by decorated ZnO nanoparticles through predictive ReaxFF molecular dynamics simulations. Nanoscale 14:36, pages 13123-13131.
Crossref
Crossref
Ola Landgren, Katja Weisel, Laura Rosinol, Cyrille Touzeau, Mehmet Turgut, Roman Hajek, Peter Mollee, Jin Seok Kim, Natalie Shu, Xuguang Hu, Chuang Li & Saad Z. Usmani. (2022)
Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the
CANDOR
study
. British Journal of Haematology 198:6, pages 988-993.
Crossref
Crossref
Magdalena Oroń, Marcin Grochowski, Akanksha Jaiswar, Justyna Legierska, Kamil Jastrzębski, Magdalena Nowak-Niezgoda, Małgorzata Kołos, Wojciech Kaźmierczak, Tomasz Olesiński, Małgorzata Lenarcik, Magdalena Cybulska, Michał Mikula, Alicja Żylicz, Marta Miączyńska, Katharina Zettl, Jacek R. Wiśniewski & Dawid Walerych. (2022) The molecular network of the proteasome machinery inhibition response is orchestrated by HSP70, revealing vulnerabilities in cancer cells. Cell Reports 40:13, pages 111428.
Crossref
Crossref
Igor Valentim Barreto, Caio Bezerra Machado, Davi Benevides Almeida, Flávia Melo Cunha de Pinho Pessoa, Renan Brito Gadelha, Laudreísa da Costa Pantoja, Deivide de Sousa Oliveira, Rodrigo Monteiro Ribeiro, Germison Silva Lopes, Manoel Odorico de Moraes Filho, Maria Elisabete Amaral de Moraes, André Salim Khayat, Edivaldo Herculano Correa de Oliveira & Caroline Aquino Moreira-Nunes. (2022) Kinase Inhibition in Multiple Myeloma: Current Scenario and Clinical Perspectives. Pharmaceutics 14:9, pages 1784.
Crossref
Crossref
Dilara AKÇORA YILDIZ, Yakuphan BAYKAN & Fadime AŞIK. (2022) Proteozom inhibitörü Carfilzomib’in multipl miyelom hücrelerinde piroptozis hücre ölüm yolağı üzerine olan etkisiThe effect of proteasome inhibitor Carfilzomib on pyroptosis cell death pathway in multiple myeloma cells. Mustafa Kemal Üniversitesi Tıp Dergisi 13:46, pages 132-137.
Crossref
Crossref
Ru Li, Hikari Okada, Taro Yamashita, Kouki Nio, Han Chen, Yingyi Li, Tetsuro Shimakami, Hajime Takatori, Kuniaki Arai, Yoshio Sakai, Tatsuya Yamashita, Eishiro Mizukoshi, Masao Honda & Shuichi Kaneko. (2022) FOXM1 Is a Novel Molecular Target of AFP-Positive Hepatocellular Carcinoma Abrogated by Proteasome Inhibition. International Journal of Molecular Sciences 23:15, pages 8305.
Crossref
Crossref
Shahaf Tuler, Jaspreet Kaur & Constantin A. Dasanu. (2022) Cecal volvulus associated with carfilzomib use for al amyloidosis. Journal of Oncology Pharmacy Practice 28:5, pages 1230-1233.
Crossref
Crossref
Javaria Ahmad, Aswani Thurlapati, Sahith Thotamgari, Udhayvir Singh Grewal, Aakash Rajendra Sheth, Dipti Gupta, Kavitha Beedupalli & Paari Dominic. (2022) Anti-cancer Drugs Associated Atrial Fibrillation—An Analysis of Real-World Pharmacovigilance Data. Frontiers in Cardiovascular Medicine 9.
Crossref
Crossref
Yuka Kawaji‐Kanayama, Tsutomu Kobayashi, Ayako Muramatsu, Hitoji Uchiyama, Nana Sasaki, Nobuhiko Uoshima, Mitsushige Nakao, Ryoichi Takahashi, Kazuho Shimura, Hiroto Kaneko, Miki Kiyota, Katsuya Wada, Yoshiaki Chinen, Koichi Hirakawa, Shin‐ichi Fuchida, Chihiro Shimazaki, Yayoi Matsumura‐Kimoto, Shinsuke Mizutani, Taku Tsukamoto, Yuji Shimura, Shigeo Horiike, Masafumi Taniwaki & Junya Kuroda. (2021) Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib‐based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients. Cancer Reports 5:2.
Crossref
Crossref
Saad Z Usmani, Hang Quach, Maria-Victoria Mateos, Ola Landgren, Xavier Leleu, David Siegel, Katja Weisel, Maria Gavriatopoulou, Albert Oriol, Neil Rabin, Ajay Nooka, Ming Qi, Meral Beksac, Andrzej Jakubowiak, Bifeng Ding, Anita Zahlten-Kumeli, Akeem Yusuf & Meletios Dimopoulos. (2022) Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. The Lancet Oncology 23:1, pages 65-76.
Crossref
Crossref
Angela Rago, Agostina Siniscalchi, Attilio Tordi, Cristina Andrizzi, Selenia Campagna & Tommaso Caravita di Toritto. (2021) Pulmonary arterial hypertension in a patient with multiple myeloma during carfilzomib treatment: in search of better management. Tumori Journal 107:6, pages NP37-NP40.
Crossref
Crossref
Shansa Pranami E. Jayaweera, Sacheela Prasadi Wanigasinghe Kanakanamge, Dharshika Rajalingam & Gayathri N. Silva. (2021) Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma. Frontiers in Oncology 11.
Crossref
Crossref
Jeong-Su Park, Hwan Ma & Yoon-Seok Roh. (2021) Ubiquitin pathways regulate the pathogenesis of chronic liver disease. Biochemical Pharmacology 193, pages 114764.
Crossref
Crossref
Joana M. O. Santos, Alexandra C. Costa, Tânia R. Dias, Setareh Satari, Maria Paula Costa e Silva, Rui M. Gil da Costa & Rui Medeiros. (2021) Towards Drug Repurposing in Cancer Cachexia: Potential Targets and Candidates. Pharmaceuticals 14:11, pages 1084.
Crossref
Crossref
Luciano J. Costa, Faith E. DaviesGregory P. MonohanTibor KovacsovicsNicholas BurwickAndrzej JakubowiakJonathan L. Kaufman, Wan-Jen HongMonique Dail, Ahmed Hamed SalemXiaoqing YangAbdullah A. MasudWijith MunasingheJeremy A. RossOrlando F. BuenoShaji K. Kumar & Edward A. Stadtmauer. (2021) Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Advances 5:19, pages 3748-3759.
Crossref
Crossref
Rafael Klimas, Melissa Sgodzai, Jeremias Motte, Nuwin Mohamad, Pia Renk, Alina Blusch, Thomas Grüter, Xiomara Pedreiturria, Philipp Gobrecht, Dietmar Fischer, Christiane Schneider-Gold, Anke Reinacher-Schick, Andrea Tannapfel, Min-Suk Yoon, Ralf Gold & Kalliopi Pitarokoili. (2021) Dose-dependent immunomodulatory effects of bortezomib in experimental autoimmune neuritis. Brain Communications 3:4.
Crossref
Crossref
Karthik Ramasamy, Francesca Gay, Katja Weisel, Sonja Zweegman, Maria Victoria Mateos & Paul Richardson. (2021) Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options. Blood Reviews 49, pages 100808.
Crossref
Crossref
Katie Dunphy, Paul Dowling, Despina Bazou & Peter O’Gorman. (2021) Current Methods of Post-Translational Modification Analysis and Their Applications in Blood Cancers. Cancers 13:8, pages 1930.
Crossref
Crossref
Vera Vozandychova, Pavla Stojkova, Kamil Hercik, Pavel Rehulka & Jiri Stulik. (2021) The Ubiquitination System within Bacterial Host–Pathogen Interactions. Microorganisms 9:3, pages 638.
Crossref
Crossref
Raquel Lopes, Bruna Velosa Ferreira, Joana Caetano, Filipa Barahona, Emilie Arnault Carneiro & Cristina João. (2021) Boosting Immunity against Multiple Myeloma. Cancers 13:6, pages 1221.
Crossref
Crossref
Swetha Kambhampati, Bita Fakhri, Weiyun Z. Ai, Lawrence D. Kaplan, Joseph M. Tuscano, Matthew J. Wieduwilt, Akshay Sudhindra, Erika Cavallone, Jesika Reiner, Charlie Aoun, Miguel Castillo, Michelle Martinelli, Teresa Ta, Diem Le, Michelle Padilla, Erika Crawford & Charalambos B. Andreadis. (2021) Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial. Clinical Lymphoma Myeloma and Leukemia 21:3, pages 139-146.
Crossref
Crossref
Laure Maneix, Melanie A. Sweeney, Sukyeong Lee, Polina Iakova, Shannon E. Moree, Ergun Sahin, Premal Lulla, Sarvari V. Yellapragada, Francis T. F. Tsai & Andre Catic. (2021) The Mitochondrial Protease LonP1 Promotes Proteasome Inhibitor Resistance in Multiple Myeloma. Cancers 13:4, pages 843.
Crossref
Crossref
Karyne Pelletier, Marko Škrtić & Abhijat Kitchlu. (2021) Cancer therapy-induced hyponatremia: A case-illustrated review. Journal of Onco-Nephrology 5:1, pages 70-78.
Crossref
Crossref
Yang Bai & Xing Su. (2020) Updates to the drug‐resistant mechanism of proteasome inhibitors in multiple myeloma. Asia-Pacific Journal of Clinical Oncology 17:1, pages 29-35.
Crossref
Crossref
Grace Lassiter, Cole Bergeron, Ryan Guedry, Julia Cucarola, Adam M. Kaye, Elyse M. Cornett, Alan D. Kaye, Giustino Varrassi, Omar Viswanath & Ivan Urits. (2021) Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects. Current Oncology 28:1, pages 640-660.
Crossref
Crossref
Amber Afzal, Mark A. Fiala, Brian F. Gage, Tanya M. Wildes & Kristen Sanfilippo. (2020) Statins Reduce Mortality in Multiple Myeloma: A Population-Based US Study. Clinical Lymphoma Myeloma and Leukemia 20:12, pages e937-e943.
Crossref
Crossref
Alexa N. Carrera, Marianne K.O. Grant & Beshay N. Zordoky. (2020) CYP1B1 as a therapeutic target in cardio-oncology. Clinical Science 134:21, pages 2897-2927.
Crossref
Crossref
Xabier Gutiérrez López de Ocáriz, Clara Cuéllar Pérez-Ávila & Joaquín Martínez López. (2020) Análisis descriptivo del perfil de toxicidad del carfilzomib en pacientes con mieloma múltiple. Experiencia en un centro español de tercer nivel. Medicina Clínica Práctica 3:6, pages 100085.
Crossref
Crossref
Alistair S. Brown, David F. Ackerley & Mark J. Calcott. (2020) High-Throughput Screening for Inhibitors of the SARS-CoV-2 Protease Using a FRET-Biosensor. Molecules 25:20, pages 4666.
Crossref
Crossref
Lisa J. Crawford, David C. Campbell, Jonathan J. Morgan, Michelle A. Lawson, Jennifer M. Down, Dharminder Chauhan, Roisin M. McAvera, Treen C. Morris, Claudia Hamilton, Aswini Krishnan, Krishnaraj Rajalingam, Andrew D. Chantry & Alexandra E. Irvine. (2020) The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma. Oncogene 39:27, pages 5001-5014.
Crossref
Crossref
Changjiang Zhang, Xiuxiu Wang, Ru Cheng & Zhiyuan Zhong. (2020) A6 Peptide-Tagged Core-Disulfide-Cross-Linked Micelles for Targeted Delivery of Proteasome Inhibitor Carfilzomib to Multiple Myeloma In Vivo. Biomacromolecules 21:6, pages 2049-2059.
Crossref
Crossref
Linda Anna Michelle Kulka, Pia-Victoria Fangmann, Diana Panfilova & Heidi Olzscha. (2020) Impact of HDAC Inhibitors on Protein Quality Control Systems: Consequences for Precision Medicine in Malignant Disease. Frontiers in Cell and Developmental Biology 8.
Crossref
Crossref
Xiang Zhou, Patricia Flüchter, Katharina Nickel, Katharina Meckel, Janin Messerschmidt, David Böckle, Sebastian Knorz, Maximilian Johannes Steinhardt, Franziska Krummenast, Sophia Danhof, Hermann Einsele, K. Martin Kortüm & Leo Rasche. (2020) Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease. Cancers 12:4, pages 1035.
Crossref
Crossref
Shigeki Ito. (2020) Proteasome Inhibitors for the Treatment of Multiple Myeloma. Cancers 12:2, pages 265.
Crossref
Crossref